Hypoglycemic effects of Ganoderma lucidum polysaccharides in type 2 diabetic mice

Abstract

Our aims were to investigate the hypoglycemic effects and mechanisms of action of Ganoderma lucidum polysaccharides (GLPs) administered for 7 days in type 2 diabetic mice. The mice were randomly divided into four groups (8 mice/group): normal control group, diabetic control group, low-dose GLP-treated diabetic group (50 mg/kg/d), and high-dose GLP-treated diabetic group (100 mg/kg/d). Diabetes was induced by streptozotocin injection and high-fat dietary feeding. At the end of the study, fasting serum glucose, insulin, body weight (BW) and epididymal white adipose tissue weight were measured. The hepatic mRNA levels of glycogen phosphorylase (GP), fructose-1,6-bisphosphatase (FBPase), phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6Pase) genes were determined by real-time polymerase chain reaction. Both doses of GLPs significantly decreased fasting serum glucose, insulin and epididymal fat/BW ratio compared with the diabetic control group (p < 0.05). The hepatic mRNA levels of GP, FBPase, PEPCK and G6Pase were significantly lower in both GLP-treated groups compared with the diabetic control group. Taken together, GLPs significantly decrease fasting serum glucose levels in type 2 diabetic mice in a dose-dependent manner. The decreases in fasting serum glucose levels may be associated with decreased mRNA expression levels of several key enzymes involved in gluconeogenesis and/or glycogenolysis.

Resistant starch manipulated hyperglycemia/hyperlipidemia and related genes expression in diabetic rats

“…Moreover, the expression levels of G6PC1, a key regulatory enzyme in gluconeogenesis for catalyzing the final reaction step in hepatic glucose production, and PEPCK, for catalyzing the conversion of oxaloacetate (OAA) to phosphoenolpyruvate (PEP) was down-regulated following the RS administration. Thus, the current investigation might indicate that the decrease in fasting blood glucose level might be also partially associated with decreased mRNA expression levels of PEPCK and G6PC1, which was in line with other study using Ganoderma lucidum polysaccharides for the diabetic intervention [14].…”

Development of two novel specific SCAR markers by cloning improved RAPD fragments from the medicinal mushroom Ganoderma lucidium (Leysser: Fr) Karst

“…Due to their significant medicinal importance, mushrooms of the Ganoderma species have gained noticeable interest from biomedical researchers. A number of studies have revealed the medicinal values of Ganoderma mushrooms against various life-threatening diseases and health complications like cancer, immunodeficiency, cardiovascular complications, diabetes, hepatic disease, neurodegeneration, and infectious disease (Hajjaj et al, 2005;Paterson, 2006;Ma et al, 2011;Chu et al, 2012;Tie et al, 2012;Xiao et al, 2012;Boh, 2013;Wang et al, 2013;Wu et al, 2013;Yue et al, 2013). There are numerous variations in the size, shape, and color of Ganoderma mushrooms, and they differ in biological properties as well.…”

Antidiabetic effect of total saponins from Polygonatum kingianum in streptozotocin-induced daibetic rats

“…The antihyperglycemic effects of several plant extracts and herbal prescriptions, which are used as antidiabetic formulations, have been confirmed Sun et al, 2015;Wang et al, 2012;Xiao et al, 2012;Xie et al, 2011;Zhang et al, 2015). Polygonati Rhizoma, first P. kingianum is widely reported and used as adjuvant therapy drug of diabetes in favor of its blood glucose level lowing effects ( Chen et al, 2001;Deng et al, 2012;Kato and Miura, 1994;Roh et al, 2008;).…”